

01-28-05

IFW

DOCKET NO.: ISIS-5207

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of:**

**Brenda F. Baker, et al.**

**Confirmation No.: 5280**

**Application No.: 10/701,236**

**Group Art Unit: 1635**

**Filing Date: November 4, 2003**

**Examiner: Not Yet Assigned**

**For: SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND  
COMPOSITIONS FOR USE IN GENE MODULATION**

**EXPRESS MAIL LABEL NO: EL998518587US**

**DATE OF DEPOSIT: January 26, 2005**

**EL998518587US**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

- ☐ Certification in Accordance with § 1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **224 – 227 and 234** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **228 - 233** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).


- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

- ☐ The relevance of those listed references which are not in the English language is as follows:


There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: January 25, 2005

  
\_\_\_\_\_  
John A. Harrelson, Jr.  
Registration No. 42,637

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5207	Application No. 10/701,236
	Applicant Brenda F. Baker, et al.	
	Filing Date November 4, 2003	Group 1635
	Confirmation No. 5280	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

*	224	Amarzguioui, M., et al., "Tolerance for mutations and chemical modifications in a siRNA," <i>Nucleic Acids Res.</i> , <b>2003</b> , <i>31</i> (2), 589-595
**	225	Bass, B.L., "Double-stranded RNA as a template for gene silencing," <i>Cell</i> , <b>2000</b> , <i>101</i> , 235-238
****	226	Elbashir, S.M., "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes &amp; Devel.</i> , <b>2001</b> , <i>15</i> , 188-200
**	227	Lipardi, C., et al., "RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs," <i>Cell</i> , <b>2001</b> , <i>107</i> , 297-307

**EXAMINER**

**DATE CONSIDERED**

\* Cited on PCT International Search Report dated January 6, 2005 (PCT/US03/35071).

\*\* Cited on PCT International Search Report dated January 10, 2005 (PCT/US03/35067).

\*\*\*\*Cited on PCT International Search Report dated January 7, 2005 (PCT/US03/35061).



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. ISIS-5207		Application No. 10/701,236	
				Applicant Brenda F. Baker, et al.			
				Filing Date November 4, 2003		Group 1635	
				Confirmation No. 5280			
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Name	Class	Subclass	
****	228	5,602,240	02/11/97	De Mesmaeker, et al.	536	22.1	
***	229	6,150,510	11/21/00	Seela, et al.	536	22.1	
***	230	6,294,522 B1	09/25/01	Zablocki, et al.	541	46	
***	231	2002/0160393 A1	10/31/02	Symonds, et al.	435	6	
*	232	2003/0143732 A1	07/31/03	Fosnaugh, et al.	435	325	
*	233	2003/0206887 A1	11/06/03	Morrissey, et al.	424	93.2	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
**	234	WO 03/072705 A2	09/04/03	PCT			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

- \* Cited on PCT International Search Report dated January 6, 2005 (PCT/US03/35071).
- \*\* Cited on PCT International Search Report dated January 10, 2005 (PCT/US03/35067).
- \*\*\*Cited on PCT International Search Report dated January 4, 2005 (PCT/US03/35146).
- \*\*\*\*Cited on PCT International Search Report dated January 7, 2005 (PCT/US03/35061).